Does Recombinant Human Erythropoietin Affect Plasma Lipids in Hemodialysis Patients?

Does recombinant human erythropoietin affect plasma lipids in hemodialysis patients?

Prof. Dr. Kuddusi Cengiz, Ondokuz Mayis University School of Medicine, Department of Nephrology, TR-55139 Samsun (Turkey) Dear Sir, The correction of anemia in hemodialysis patients with human recombinant erythropoietin increases appetite, anabolic effects, and improves physical, psychological activities and endocrine functions. As the sense of well-being improves, the patients increase food in...

Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.

Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients.

INTRODUCTION We sought to examine the impact of ergocalciferol (ERGO) on recombinant human erythropoietin (EPO) use in a cohort of 25-OH vitamin D (25-D)-deficient hemodialysis (HD) patients. METHODS Baseline 25-D levels were obtained for all patients who received HD >6 months in our unit. Patients with levels between 10 and 30 ng/mL received ERGO 50,000 IU x 4 doses and patients with levels ...

[Different response to human recombinant erythropoietin in patients undergoing hemodialysis treatment].

INTRODUCTION Treatment with recombinant human erythropoietin enabled the correction of anemia in the patients on regular hemodialysis but large individual differences in the dose required to achieve the target hemoglobin level were observed. In this study the erythropoietin resistance index was calculated in patients on hemodialysis in order to examine variations in the response to erythropoiet...

Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients.

AIM The aim of this work was to evaluate the neutrophil activation state in chronic kidney disease (CKD) patients under hemodialysis, and its linkage with resistance to recombinant human erythropoietin (rhEPO) therapy. METHODS We studied 63 CKD patients under hemodialysis and rhEPO treatment (32 responders and 31 non-responders to rhEPO therapy). In 20 of the CKD patients (10 responders and 1...